- Affirmative Recovery
- American Indian Law and Policy
- Antitrust and Trade Regulation
- Appellate Advocacy and Guidance
- Business Litigation
- Civil Rights and Police Misconduct
- Class Action Litigation
- Commercial/Project Finance and Real Estate
- Corporate Governance and Special Situations
- Corporate Restructuring and Bankruptcy
- Domestic and International Arbitration
- Ediscovery
- Health Care Litigation
- Insurance and Catastrophic Loss
- Intellectual Property and Technology Litigation
- Litigation Support Services
- Mass Tort Attorneys
- Medical Malpractice Attorneys
- Personal Injury Attorneys
- Telecommunications Litigation and Arbitration
- Wealth Planning, Administration, and Disputes
-
February 22, 2021Robins Kaplan Expands Health Care Litigation Group
-
February 1, 2021Meegan Hollywood Selected to Join American Antitrust Institute Advisory Board
-
January 28, 2021Human Rights Campaign Names Robins Kaplan LLP a “Best Place to Work for LGBTQ Equality” for the Thirteenth Consecutive Year
-
March 6, 2021With Our Voices 2021 Arc Gala
-
March 6, 20211st Annual Tee It Up for the Troops Winter Outing
-
March, 9, 2021The New Frontier of Software License Disputes
-
Winter 2021Pro Bono Publico–For The Public Good
-
Winter 2021The Case for Charitable Giving
-
Winter 2021The Fictional Wealth Disputes That We Took In and Learned From in 2020
-
February 25, 2021Financial Daily Dose 2.25.2021 | Top Story: McKinsey Ousts Managing Partner on Heels of Opioid Settlement
-
February 24, 2021Financial Daily Dose 2.24.2021 | Top Story: Chair Powell Promises Continued Fed Support for US Economy
-
February 23, 2021Financial Daily Dose 2.23.2021 | Top Story: SoftBank Nears Deal With WeWork’s Neumann for $500M Share Purchase
JUUL and the Youth Vaping Epidemic – FDA and President Trump Step In
September 13, 2019
On September 9, 2019, the FDA sent two warning letters to JUUL Labs, Inc., the maker of the popular JUUL e-cigarette.1 One letter focused on JUUL’s violation of federal regulations by advertising its vaping product as healthier than traditional combustible cigarettes.2 In finding that JUUL had promoted its product as “lower risk” or “less harmful,” the FDA referenced testimony from JUUL employees before a United States House of Representatives Subcommittee, documents seized from JUUL by the FDA, and JUUL’s own website.3
The FDA was particularly concerned about JUUL’s statements that its products were “99% safer than cigarettes,” “much safer” than cigarettes, “totally safe,” and “a safer alternative than smoking cigarettes” were made directly to children in school.4 The FDA’s concern was “amplified by the epidemic rate of increase in youth use of ENDS [electronic nicotine delivery system] products, including JUUL’s products, and evidence that ENDS products contribute to youth use of, and addiction to, nicotine.”5
The second letter focused on JUUL’s marketing to young people.6 In it, the FDA noted that:
JUUL products continue to represent a significant proportion of the overall use of ENDS products by children. We believe you have a continuing responsibility to take action to address the epidemic of youth use of your products, some of which appears to have been a direct result of your product design and marketing campaigns….7
The FDA was particularly troubled by testimony from the subcommittee that suggested JUUL had participated in outreach to schools, churches, veterans groups, and tribes, sometimes offering free samples (in the case of one tribe) and other times offering to pay schools money in exchange for the school implementing JUUL-created anti-vaping curriculum.8
The FDA’s September 9 letters adds to the growing pile of regulatory inquiries JUUL is facing. Currently, the FDA and CDC are investigating more than 450 people who have become sick with a vaping-related illness, which has resulted in six deaths.9 On September 7, 2019, the FDA issued a consumer update, warning consumers against the use of vaping products purchased on the street, or modifying/adding substances to any products purchased in stores.10
In addition to lung injuries, the FDA has also issued warnings regarding seizures and vaping,11 and the Journal of the American College of Cardiology published an article linking vaping to cardiovascular disease.12
On September 11, President Trump suggested that he was considering a ban of all flavored e-cigarettes.13
[1] https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/juul-labs-inc-590950-09092019
[2] Id.
[3] Id.
[4] Id.
[5] Id.
[6] https://www.fda.gov/media/130604/download
[7] Id.
[8] Id.
[9] https://www.nytimes.com/2019/09/09/health/vaping-juul-e-cigarettes-fda.html
[10] https://www.fda.gov/consumers/consumer-updates/vaping-illnesses-consumers-can-help-protect-themselves-avoiding-tetrahydrocannabinol-thc-containing
[11] https://www.fda.gov/news-events/fda-brief/fda-brief-fda-encourages-continued-submission-reports-related-seizures-following-e-cigarette-use
[12] http://www.onlinejacc.org/content/73/21/2722
[13] https://www.nytimes.com/2019/09/11/health/trump-vaping.html
Related Publications
Related News
If you are interested in having us represent you, you should call us so we can determine whether the matter is one for which we are willing or able to accept professional responsibility. We will not make this determination by e-mail communication. The telephone numbers and addresses for our offices are listed on this page. We reserve the right to decline any representation. We may be required to decline representation if it would create a conflict of interest with our other clients.
By accepting these terms, you are confirming that you have read and understood this important notice.